LEIDEN, the Netherlands, May 23, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the appointment of Dr.
This virtual event on March 29, 2023 featured presentations by ProQR Management on the company's proprietary Axiomer® RNA editing technology platform, detailed the initial pipeline targets, and provided guidance on the advancement of programs toward the clinic. ProQR also reported its 2022 year-end financials and the extension of its cash runway guidance.
… ODD from FDA and pre-clinical data was presented at two scientific meetings. QR-313 is expected to enter the clinic … and Thaddeus (Ted) Dryja appointed to ProQR’s ScientificAdvisoryBoard (SAB). In vivo proof of concept data for novel Axiomer …
